Allianz Asset Management
LXRX icon

Allianz Asset Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Allianz Asset Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-239,700
Closed -$3.64M – 1810
2013
Q2 		$3.64M Buy
+239,700
New +$3.64M 0.01% 1000

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Allianz Asset Management's LXRX Position: Q3 2013 in Review

Allianz Asset Management sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2013, closing a stake of 239,700 shares — an estimated $3.64M sold.

Allianz Asset Management first reported a position in LXRX in Q2 2013 and held it in 1 quarter. The position peaked at $3.64M in Q2 2013. 102 funds tracked by Wall St. Rank hold LXRX as of Q3 2013.

  • Allianz Asset Management reported no remaining Lexicon Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Allianz Asset Management sold 239,700 Lexicon Pharmaceuticals shares in Q3 2013, an estimated $3.64M.
  • Allianz Asset Management first reported a position in Lexicon Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Allianz Asset Management's Lexicon Pharmaceuticals position peaked at $3.64M in Q2 2013.
  • 102 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2013.

Based on Allianz Asset Management's 13F filing for Q3 2013, filed 14 Nov 2013.